Deep Bio successfully integrates DeepDx Prostate algorithm into HALO AP platform from Indica Labs

Deep Bio, a company concentrating on SaMD (Software as a Medical Device) for digital pathology, offering clinically validated, AI-based DeepDx algorithms, and Indica Labs, a leading provider of computational pathology software and services, are excited to announce the successful integration of the DeepDx Prostate algorithm into the HALO AP platform from Indica Labs.

DeepDx Prostate is a CE-marked, AI-based image analysis algorithm that detects prostate cancer in core needle biopsies and grades their severity according to the Gleason scoring system. DeepDx Prostate is designed to alleviate the shortage of pathologists and their heavy workload, while reducing diagnostic subjectivity and variability. Validation testing of the DeepDx algorithm, published in Modern Pathology 2022, demonstrated 99% sensitivity and 97% specificity. The algorithm is also extensively tested in real clinical workflows, analyzing over 700,000 cores between 2019 and 2021.

Recommended AI News: Netskope Acquires Infiot, Will Deliver Fully Integrated, Single-Vendor SASE Platform

The HALO AP platform was developed by Indica Labs to address the specific needs of anatomic pathology labs by supporting a wide range of tissue-based workflows, including primary diagnosis, secondary consults, tumor boards, clinical trials, synoptic reporting, quantitative analytics, and AI. HALO AP incorporates state-of-the-art workflow management tools allowing users to easily integrate quantitative analytics and AI tools built using HALO, HALO AI and third-party algorithms, such as DeepDx. To simplify integration, a HALO AP analysis software development kit (SDK) including sample code is available to all algorithm developers. One of the key advantages of HALO AP is the ability to deliver AI algorithms in an automated, stepwise workflow that can be locked, secured, and audited to prevent tampering or misuse.

DeepDx Prostate analysis can be triggered directly in HALO AP by selecting the DeepDx workflow or run automatically via the HALO AP API. Analysis progress, all results, and visual markup images can be reviewed in HALO AP, removing the need to shift between systems.

Recommended AI News: Berkshire Grey and FedEx Expand Their Robotic Automation Solutions Relationship

Steven Hashagen, CEO at Indica Labs commented, “As digital pathology continues to enable AI-based workflows, we’ve recognized that to increase efficiency, case management systems like HALO AP must support full integration of algorithms without sacrificing usability. The integration between DeepDx and HALO AP demonstrates how any algorithm vendor can leverage HALO AP to deliver clinically relevant results directly within the pathologists’ viewing software, eliminating the need for an AI-specific viewer.”

Sun Woo Kim, CEO at Deep Bio commented, “Deep Bio’s partnership with Indica Labs is a step closer to our vision and goal of providing diagnostic support tools for pathologists and oncologists, for timely and accurate diagnosis and prognosis, leading to better treatment decision-making. We believe DeepDx Prostate is a powerful addition to the robust clinical workflow afforded by HALO AP.”

Recommended AI News: Extreme Networks Enriches Partner Program with New Perks and Benefits